Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Epirubicin + Valproic acid|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Epirubicin||Ellence||Epirubicin Hydrochloride||Chemotherapy - Anthracycline 11||Ellence (epirubicin) is an anthracycline, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Ellence (epirubicin) is FDA approved as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement for primary breast cancer (FDA.gov).|
|Valproic acid||Stavzor||Depacon|Valproate Sodium|Depakene||HDAC Inhibitor 38||Valproic acid inhibits HDAC activity, potentially resulting in decreased angiogenesis, increased tumor cell differentiation, and reduced tumor growth (PMID: 11742974, PMID: 14978230). Valproic acid is FDA-approved for use in treating seizures (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Epirubicin + Valproic acid||Phase I||Actionable||In a Phase I trial, Valproic acid combined with Ellence (epirubicin) demonstrated safety and efficacy in patients with advanced solid tumors (PMID: 17513804).||17513804|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|